Targeted Oncology6d
Adding 177Lu-PSMA-617 to Enzalutamide Improves Survival, QOL in mCRPC
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
ADVFN6d
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with ...
Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...
Car and Driver5d
We Take a Modern MG on a Tour of Scotland
You'd think the sight of a new MG might attract more attention ... our final stop in the country, about 40 miles to the south of Dunnet Head, mainland Scotland’s northernmost point.
Medscape1d
Efficacy, Safety and Tolerability of Escitalopram in Doses up to 50 mg in Major Depressive Disorder (MDD)
Median time to remission was 24 weeks and median dose in remission was 30 mg. No significant safety issues were identified although tolerability appeared to decline above a dose of 40 mg with 26% ...